AI, Biotech, & Venture Capital: Alex Bangash, Founder of Transpose, on Future of Startup Investing

AI, Biotech, & Venture Capital: Alex Bangash, Founder of Transpose, on Future of Startup Investing

Synopsis: Venture capital is evolving, and so is biotech. In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of VibeBio, sits down with Alex Bangash, Founder of Transpose, an investment firm backing both startups and funds. With over 20 years of experience in venture investing, Alex shares his unconventional journey from engineering to investing and how his unique perspective has shaped his approach to funding. He breaks down the shifting startup landscape, the critical role of LPs in biotech, and why AI is a game-changer for both tech and life sciences. Alex also offers sharp insights into what it takes to build a successful venture fund today and the structural shifts that are redefining the industry. Whether you're a founder, investor, or biotech enthusiast, this episode is packed with valuable lessons on navigating the future of venture capital. Biography: Alex Bangash is the Founder of Transpose Platform, an anchor fund for the most disruptive venture funds of this decade. He is also the co-founder and former CEO of Trusted Insight, a machine learning–driven platform that hosts the world’s largest network of institutional investors. Prior to TI Platform, Alex managed capital for clients at premier endowments, foundations, family offices, insurance firms, sovereign wealth funds, and pension funds since 2003. He has helped invest over $2 billion in 50 funds with a track record of investing over $1 billion in 50+ funds for institutional investors with an IRR of 30%+ and a 2x NAV. He advised the first checks in Accel, First Round Capital, Founders Fund, Emergence, Y Combinator, Khosla, SaaStr, Initialized, Crystal Towers, and Baseline. Earlier in his career, Alex was an engineer and executive at AT&T, Lucent Technologies, Bell Labs, and GE. Alex holds an MBA from the Wharton School (where he is a frequent guest lecturer); an M.Eng. in Operations Research from Cornell, and a BS in Computer Science, English, and Economics from Cornell.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(263)

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, p...

3 Elo 47min

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient l...

22 Heinä 34min

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Maalis 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Helmi 25min

Suosittua kategoriassa Tiede

rss-poliisin-mieli
rss-mita-tulisi-tietaa
tiedekulma-podcast
rss-tiedetta-vai-tarinaa
docemilia
rss-duodecim-lehti
rss-lapsuuden-rakentajat-podcast
hippokrateen-vastaanotolla
rss-hereilla
rss-ranskaa-raakana
rss-bios-podcast
utelias-mieli
filocast-filosofian-perusteet
radio-antro